Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo1 Clear all
Completed Phase 2Phase 3 Interventional Results available

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

NCT01645787
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
4-aminopyridine, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Orange, California • Poway, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Lamotrigine Augmentation in Resistant Depression

NCT00901407
View directory record Official record
Conditions
Unipolar Depression
Interventions
lamotrigine, placebo, paroxetine
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Nutritional Supplement on Mental Wellness in Adults

NCT06058364
View directory record Official record
Conditions
Low Mood
Interventions
Intervention 1 - Triglyceride, Intervention 2 - Placebo
Dietary Supplement
Lead sponsor
Pharmavite LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure

NCT00804999
View directory record Official record
Conditions
Normal Contact Lens Wear
Interventions
Clear Care, ReNu, OPTI-FREE
Drug
Lead sponsor
Christine Sindt
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 21, 2026, 9:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

NCT03014323
View directory record Official record
Conditions
Insulin Sensitivity, Oxidative Stress
Interventions
Galantamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 21, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Mifepristone 600 mg daily, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

NCT00734968
View directory record Official record
Conditions
Stress Incontinence
Interventions
Nitrofurantoin, Placebo
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 21, 2026, 9:16 AM EDT
Withdrawn Not applicable Interventional

Developing Individualized Strategies to Prevent Nausea and Vomiting

NCT01393288
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Genetic Polymorphisms
Interventions
Ondansetron, Lorazepam, Aprepitant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
San Francisco, California • Kansas City, Kansas • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Lymphedema Study for Arm or Leg Lymphedema

NCT02257970
View directory record Official record
Conditions
Lymphedema
Interventions
Ketoprofen, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue

NCT01661595
View directory record Official record
Conditions
Fatigue
Interventions
Sildenafil, tadalafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
50 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

NCT04541589
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Iscalimab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Suwanee, Georgia • Baton Rouge, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

NCT00613938
View directory record Official record
Conditions
Arthralgia, Bunion, Hallux Valgus, Pain
Interventions
Tapentadol (CG5503), oxycodone, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

NCT02919761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
Sitagliptin, Glimepiride, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 21, 2026, 9:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 21, 2026, 9:16 AM EDT
Not yet recruiting Phase 2 Interventional

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT07601295
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Early Phase 1 Interventional Results available

Behavioral Effects of Pregabalin and Cannabis

NCT01511640
View directory record Official record
Conditions
Cannabis-use Disorders
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

NCT04495283
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin, Acetaminophen, Placebo 1, Placebo 2
Drug · Other
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Pasadena, California • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 21, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

4-aminopyridine for Skin Wound Healing

NCT06333171
View directory record Official record
Conditions
Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 21, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

NCT04488601
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
50 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 21, 2026, 9:16 AM EDT